Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27485708 | 1.00 | CYP1A2 (0.71) | — | |
| SCHEMBL64965 | 0.97 | — | — | |
| SCHEMBL28630036 | 0.95 | — | — | |
| Monoethanolamine SCHEMBL2583170 | 0.93 | CYP1A2 (0.63) | — | |
| Hypochlorous Acid SCHEMBL9150736 | 0.93 | CYP1A2 (0.68) | — | |
| Hydrochloric Acid SCHEMBL2218353 | 0.93 | — | — | |
| SCHEMBL28147474 | 0.89 | CYP1A2 (0.63) | — | |
| Beta-Alanine SCHEMBL1878089 | 0.89 | CYP1A2 (0.63) | — | |
| Succinic Acid Diethyl Ester SCHEMBL7700334 | 0.87 | CYP1A2 (0.74) | — | |
| SCHEMBL4650134 | 0.87 | CYP1A2 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1024 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118668195-B | Electroless platinating solution, preparation method thereof and application thereof in wafer electroless platinating | 昆山一鼎工业科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118668195-A | Electroless platinating solution, preparation method thereof and application thereof in wafer electroless platinating | 昆山一鼎工业科技有限公司 | 2024-09-20 | — | — | CN | claimed |
| US-20230131180-A1 | Processes for producing amide compounds, and their crystalline and salt form | ALPHALA CO., LTD. (TW) | 2023-04-27 | — | — | US | claimed |
| CN-115960081-A | Endoplasmic reticulum targeted glutathione fluorescent probe and preparation method thereof | 青岛科技大学 | 2023-04-14 | — | — | CN | claimed |
| EP-4114823-A1 | PROCESSES FOR PRODUCING AMIDE COMPOUNDS, AND THEIR CRYSTALLINE AND SALT FORM | Alphala Co., Ltd. (TW) | 2023-01-11 | — | — | EP | claimed |
| CN-115052855-A | Preparation method of amide compound, crystal form and salt thereof | 昊运股份有限公司 | 2022-09-13 | — | — | CN | claimed |
| CN-110684028-B | Preparation method of 2, 6-diazabicyclo [3,3,0] octane compound | 上海阿拉丁生化科技股份有限公司 | 2021-10-26 | — | — | CN | claimed |
| WO-2021178486-A1 | PROCESSES FOR PRODUCING AMIDE COMPOUNDS, AND THEIR CRYSTALLINE AND SALT FORM | ALPHALA CO., LTD. (TW) | 2021-09-10 | — | — | WO | claimed |
| CN-110684028-A | Preparation method of 2, 6-diazabicyclo [3, 3, 0] octane compound | 上海阿拉丁生化科技股份有限公司 | 2020-01-14 | — | — | CN | claimed |
| EP-4039257-B1 | PHARMACEUTICAL COMPOSITION AND KIT CONTAINING A PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM BETA-LACTAMASE INHIBITOR COMPOUND, ANTIBACTERIAL COMPOUND AND SALTS OF THESE | FUJIFILM CORP (JP) | 2026-05-27 | — | — | EP | disclosed |
| CN-122037170-A | Two-dimensional polymer block | 复旦大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036595-A | Fentanyl hapten, complete antigen thereof and application thereof | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-0065963-A1 | COMPOUNDS AND METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1982-12-08 | — | — | EP | disclosed |
| WO-1982001870-A1 | COMPOUNDS AND METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS | AMERICAN HOSPITAL SUPPLY CORP (US) | 1982-06-10 | — | — | WO | disclosed |
| EP-0053434-A1 | Compounds and method for treatment or prophylaxis of cardiac disorders | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1982-06-09 | — | — | EP | disclosed |
| US-4258058-A | Phenoxyalkylcarboxylic acid compounds and thrombocyte-aggregation inhibition | BOEHRINGER MANNHEIM GMBH (DE) | 1981-03-24 | — | — | US | disclosed |
| EP-0004011-A1 | Phenoxyalkylcarboxylic-acid derivatives, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1979-09-19 | — | — | EP | disclosed |
| US-4136197-A | HYPOGLYCAEMICALLY AND HYPOLIPIDAEMICALLY EFFECTIVE N-SUBSTITUTED CARBOXYLIC ACID AMIDES | BOEHRINGER MANNHEIM GMBH (DE) | 1979-01-23 | — | — | US | disclosed |